Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Cardiology imaging study urges use of intravascular imaging for PCI guidance

A new review from the American College of Cardiology’s Interventional Council strongly suggests that intracoronary imaging should now be a routine part of clinical practice, as it can be used to assess the lesion prior...

February 14, 2023

Markets

Cantor starts MoonLake at OW; PT $23

Cantor Fitzgerald initiated coverage of MoonLake Immunotherapeutics (NASDAQ:MLTX) with an “overweight” rating and a 12-month price target of $23. The stock closed at $16.30 on Feb. 13. MoonLake has an IL-17A and IL-17F...

February 14, 2023

Markets

HCW starts OmniAb at buy; PT $11

H.C. Wainwright launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and a price target of $11. The stock closed at $3.88 on Feb. 10. At its core, OmniAb is an antibody discovery, optimization, and licensing...

February 13, 2023

Developments

Cognition completes enrollment in Phase 2 SEQUEL study in AD

Cognition Therapeutics (NASDAQ:CGTX) completed enrollment in the randomized, double-blind Phase 2 SEQUEL study of its CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease. The study was designed to assess...

February 9, 2023

Developments

SeaStar Medical to begin AKI device study to reduce hyperinflammation in adults

The FDA approved SeaStar Medical’s (NASDAQ:ICU) investigational device exemption application to conduct a pivotal study evaluating the effectiveness of its Selective Cytopheretic Device (SCD) in reducing...

February 9, 2023

Developments

Abbott to acquire Cardiovascular Systems for $890-million

Abbott (NYSE:ABT) agreed to acquire Cardiovascular Systems, Inc. (NASDAQ:CSII) for $20 a share or approximately $890-million. Cardiovascular Systems is a leader in devices for atherectomy, a minimally invasive treatment...

February 9, 2023

Developments

IntelGenx in research collaboration with renowned neurologist for Montelukast VersaFilm in PD

IntelGenx (TSX:IGX; OTCQB:IGXT) announced a research collaboration with Per Svenningsson, M.D., Ph.D., of the Karolinska Institute, to plan and conduct a multicentre, randomized, double-blind, placebo-controlled...

February 9, 2023

Developments

NeuroSense cleared in Germany to enroll patients in Phase 2b ALS trial

Germany’s Federal Institute for Drugs and Medical Devices approved NeuroSense Therapeutics’ (NASDAQ:NRSN) clinical trial application to enroll patients in PARADIGM, a Phase 2b study of its lead combination drug...

February 8, 2023

Developments

Annovis Bio to expand Phase 3 PD study of buntanetap to EU

Annovis Bio (NYSE:ANVS) received approval to open 48 clinical trial sits in five European Union countries for its ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (PD). The company is...

February 8, 2023

Developments

SynaptixBio gets FDA rare pediatric disease nod for TUBB4a leukodystrophy

Dr. Dan Williams, CEO and Co-founder The FDA granted a rare pediatric disease (RPD) designation to closely-held SynaptixBio of the UK to develop the first treatment for TUBB4A leukodystrophy, a rare genetic and...

February 7, 2023

Developments

Tonix starts Phase 2 intranasal oxytocin study in chronic migraine

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVENTION study of TNX-1900 (intranasal potentiated oxytocin) for the prevention of chronic migraine headache. The double-blind, placebo...

February 6, 2023

Markets

Cantor starts Outlook Therapeutics at OW; PT $4

Cantor Fitzgerald launched coverage of Outlook Therapeutics (NASDAQ:OTLK) with an “overweight” rating and a 12-month price target of $4. The stock closed at $1.15 on Feb. 3. Outlook is a biopharmaceutical company that...

February 6, 2023

Cardiology imaging study urges use of intravascular imaging for PCI guidance

Cantor starts MoonLake at OW; PT $23

HCW starts OmniAb at buy; PT $11

Cognition completes enrollment in Phase 2 SEQUEL study in AD

SeaStar Medical to begin AKI device study to reduce hyperinflammation in adults

Abbott to acquire Cardiovascular Systems for $890-million

IntelGenx in research collaboration with renowned neurologist for Montelukast VersaFilm in PD

NeuroSense cleared in Germany to enroll patients in Phase 2b ALS trial

Annovis Bio to expand Phase 3 PD study of buntanetap to EU

SynaptixBio gets FDA rare pediatric disease nod for TUBB4a leukodystrophy

Tonix starts Phase 2 intranasal oxytocin study in chronic migraine

Cantor starts Outlook Therapeutics at OW; PT $4

General

More